Physician profile
Stephen J Bruce
NPI 1841269321
$2,903.62
in general payments reported to CMS, 2019-2025
33 companies · $19.83 in 2025
The $19.83 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $675 · 2020: $741 · 2021: $1,367 · 2022: $50.12 · 2024: $50.72 · 2025: $19.83.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $70.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $70.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $737.59 | 2019-2021 | |
| Abbvie INC. | $425.96 | 2019-2022 | |
| Astellas Pharma US INC | $164.37 | 2019-2021 | |
| Lilly USA, LLC | $156.46 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $155.92 | 2019-2021 | |
| Glaxosmithkline, LLC. | $141.74 | 2019-2021 | |
| Amgen INC. | $105.96 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $94.24 | 2021 | |
| Sanofi-Aventis U.S. LLC | $91.37 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $85.13 | 2019-2021 | |
| Dynavax Technologies Corporation | $70.91 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.30 | 2019-2021 | |
| Pfizer INC. | $59.34 | 2019-2021 | |
| Genentech USA, INC. | $58.35 | 2019-2021 | |
| Allergan, INC. | $56.65 | 2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $50.72 | 2024 | Sunosi |
| Takeda Pharmaceuticals U.S.A., INC. | $48.57 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $45.97 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $42.63 | 2020-2021 | |
| Eisai INC. | $34.60 | 2020-2021 | |
| Qiagen, LLC | $27.76 | 2020 | |
| Novartis Pharmaceuticals Corporation | $26.07 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $24.87 | 2021 | |
| Novo Nordisk INC | $24.58 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $23.19 | 2019-2020 | |
| Si-Bone, INC. | $19.83 | 2025 | |
| Sanofi Pasteur INC. | $15.77 | 2020 | |
| Biogen, INC. | $15.19 | 2021 | |
| Medtronic, INC. | $12.46 | 2021 | |
| Antares Pharma, INC. | $11.57 | 2019 | |
| Assertio Therapeutics, INC. | $11.55 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Bruce listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.